Loading clinical trials...
Loading clinical trials...
Specific Use-Results Survey of TAKHZYRO Subcutaneous Injection 300 mg Syringe for Hereditary Angioedema With Long-term Administration
Conditions
Interventions
Lanadelumab
Locations
1
Japan
Takeda selected site
Tokyo, Tokyo, Japan
Start Date
May 30, 2022
Primary Completion Date
June 25, 2026
Completion Date
June 25, 2026
Last Updated
April 13, 2026
NCT07298447
NCT06842823
NCT05396105
NCT05469789
NCT07428499
NCT05819775
Lead Sponsor
Takeda
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions